Access the full text.
Sign up today, get DeepDyve free for 14 days.
Wei-shu Wang, Jen‐Kou Lin, T. Chiou, Jin-Hwang Liu, F. Fan, C. Yen, Tzu-chen Lin, Jeng‐Kae Jiang, Shung-Haur Yang, Huann‐Sheng Wang, Po-min Chen (2002)CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
Hepato-gastroenterology, 49 43
G. Kornek, T. Schenk, M. Raderer, M. Djavarnmad, W. Scheithauer (1995)Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours.
British Journal of Cancer, 71
K. Yamashita, M. Watanabe (2009)Clinical significance of tumor markers and an emerging perspective on colorectal cancer
Cancer Science, 100
B. Glimelius, K. Hoffman, R. Einarsson, L. Pählman, W. Graf (1996)Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements.
Acta oncologica, 35 2
E. Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. Dibartolomeo, M. Mazier, J. Canon, V. Georgoulias, M. Peeters, J. Bridgewater, D. Cunningham (2009)Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 11
L. Rydlander, Elisabeth Ziegler, T. Bergman, Eva Schöberl, G. Steiner, A. Bergman, A. Zetterberg, M. Marberger, Peter Björklund, T. Skern, R. Einarsson, H. Jörnvall (1996)Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18.
European journal of biochemistry, 241 2
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)Global Cancer Statistics
V. Treska, O. Topolcan, K. Stanislav, V. Liska, L. Holubec (2009)Preoperative tumor markers as prognostic factors of colorectal liver metastases.
Hepato-gastroenterology, 56 90
R. Screaton, L. Penn, C. Stanners (1997)Carcinoembryonic Antigen, a Human Tumor Marker, Cooperates with Myc and Bcl-2 in Cellular Transformation
The Journal of Cell Biology, 137
F. Kabbinavar, J. Hambleton, R. Mass, H. Hurwitz, E. Bergsland, S. Sarkar (2005)Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 16
G. Prager, Kira Braemswig, A. Martel, M. Unseld, G. Heinze, T. Brodowicz, W. Scheithauer, G. Kornek, C. Zielinski (2014)Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
Cancer Science, 105
D. Lambrechts, H. Lenz, S. Haas, P. Carmeliet, S. Scherer (2013)Markers of response for the antiangiogenic agent bevacizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 9
Wu Zhang, M. Azuma, G. Lurje, M. Gordon, Dongyun Yang, A. Pohl, Y. Ning, P. Bohanes, A. Gerger, T. Winder, E. Hollywood, K. Danenberg, L. Saltz, H. Lenz (2010)Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
Anticancer research, 30 10
U. Ballehaninna, R. Chamberlain (2012)The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.
Journal of gastrointestinal oncology, 3 2
A. Berglund, D. Molin, A. Larsson, R. Einarsson, B. Glimelius (2002)Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 13 9
Kira Bramswig, M. Poettler, M. Unseld, F. Wrba, P. Uhrin, W. Zimmermann, C. Zielinski, G. Prager (2013)Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis.
Cancer research, 73 22
Ji Zhou, E. He, S. Skog (2013)The proliferation marker thymidine kinase 1 in clinical use.
Molecular and clinical oncology, 1 1
(2013)Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 10
Y. Narita, H. Taniguchi, A. Komori, Sohei Nitta, Kazuhisa Yamaguchi, C. Kondo, M. Nomura, S. Kadowaki, D. Takahari, T. Ura, M. Andoh, K. Muro (2014)CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
Cancer Chemotherapy and Pharmacology, 73
L. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzén, J. Cassidy (2023)Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of Clinical Oncology, 41
Š. Svobodová, O. Topolcan, L. Holubec, V. Treska, A. Sutnar, K. Rupert, S. Kormunda, M. Roušarová, J. Finek (2007)Prognostic importance of thymidine kinase in colorectal and breast cancer.
Anticancer research, 27 4A
A. Yuste, J. Aparicio, A. Segura, P. López-Tendero, R. Gironés, J. Pérez-Fidalgo, R. Díaz, V. Calderero (2003)Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Clinical colorectal cancer, 2 4
J. Huh, B. Oh, Hyeong-Rok Kim, Y. Kim (2010)Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer
Journal of Surgical Oncology, 101
Li-Chu Sun, K. Chu, Suyun Cheng, Chien-Yu Lu, C. Kuo, J. Hsieh, Y. Shih, Shun-Jen Chang, Jaw-Yuan Wang (2009)Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment
BMC Cancer, 9
M. Duffy, R. Lamerz, C. Haglund, A. Nicolini, M. Kalousová, L. Holubec, C. Sturgeon (2013)Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
International Journal of Cancer. Journal International du Cancer, 134
I. Park, G. Choi, K. Lim, B. Kang, S. Jun (2009)Serum Carcinoembryonic Antigen Monitoring After Curative Resection for Colorectal Cancer: Clinical Significance of the Preoperative Level
Annals of Surgical Oncology, 16
Ma Dong (2006)Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
Journal of Evidence-based Medicine
J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, P. Boyle (2006)Estimates of the cancer incidence and mortality in Europe in 2006.
Annals of oncology : official journal of the European Society for Medical Oncology, 18 3
J. Ferlay, D. Parkin, E. Steliarova-Foucher (2010)Estimates of cancer incidence and mortality in Europe in 2008.
European journal of cancer, 46 4
V. Goede, O. Coutelle, J. Neuneier, A. Reinacher-Schick, R. Schnell, T. Koslowsky, M. Weihrauch, B. Cremer, H. Kashkar, M. Odenthal, H. Augustin, W. Schmiegel, M. Hallek, U. Hacker (2010)Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
British Journal of Cancer, 103
J. Brockenbrough, J. Morihara, Stephen Hawes, Joshua Stern, Janet Rasey, L. Wiens, Q. Feng, H. Vesselle (2009)Thymidine Kinase 1 and Thymidine Phosphorylase Expression in Non-Small-cell Lung Carcinoma in Relation to Angiogenesis and Proliferation
Journal of Histochemistry & Cytochemistry, 57
L. Harrison, J. Guillem, P. Paty, A. Cohen (1997)Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients.
Journal of the American College of Surgeons, 185 1
H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright, J Hainsworth, W Heim (2004)Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer
N Engl J Med, 250
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. Glabbeke, A. Oosterom, M. Christian, S. Gwyther (2000)New guidelines to evaluate the response to treatment in solid tumors
Breast Cancer, 12
V. Formica, M. Massara, I. Portarena, V. Fiaschetti, I. Grenga, G. Blanco, P. Sileri, Livia Tosetto, F. Skoulidis, F. Pallone, M. Roselli (2009)Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Cancer biomarkers : section A of Disease markers, 5 4
P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, L Rubinstein (2000)New guidelines to evaluate the response to treatment in solid tumours. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada
J Natl Cancer Inst, 3
M. Kozloff, M. Yood, J. Berlin, P. Flynn, F. Kabbinavar, D. Purdie, M. Ashby, W. Dong, M. Sugrue, A. Grothey (2009)Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
The oncologist, 14 9
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. Glabbeke, A. Oosterom, M. Christian, S. Gwyther (2000)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
Journal of the National Cancer Institute, 92 3
Yi-fan Peng, Lin Wang, J. Gu (2012)Elevated Preoperative Carcinoembryonic Antigen (CEA) and Ki67 Is Predictor of Decreased Survival in IIA Stage Colon Cancer
World Journal of Surgery, 37
S. Benchimol, A. Fuks, S. Jothy, N. Beauchemin, K. Shirota, C. Stanners (1989)Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule
H. Bodenmüller (1995)The biochemistry of CYFRA 21-1 and other cytokeratin-tests.
Scandinavian journal of clinical and laboratory investigation. Supplementum, 221
The aim of our retrospective study was to analyze the association of selected tumor markers (TMs) including serum carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase, and tissue polypeptide specific antigen with outcomes in patients with metastatic colorectal cancer (mCRC) treated with bevacizumab. There is an increasing body of evidence from retrospective/observational studies that some serum TMs may be predictive of effect of targeted therapies in mCRC. In our study, the cohort included 152 patients treated with bevacizumab-based therapy between years 2005 and 2014 at Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen. Serum samples for measurement of TMs were collected within 1 month before the initiation of bevacizumab-based treatment. In multivariate Cox analysis that included serum tumor markers and clinical baseline parameters, the number of metastatic sites (hazard ratio [HR] = 2.00, p = 0.001) and CEA levels (HR = 2.80, p < 0.001) were significantly associated with progression-free survival, whereas CA 19-9 levels (HR = 2.25, p = 0.008) were the only studied parameter associated with overall survival. Quantification of serum CEA and CA 19-9 is simple and readily available, and their candidate prognostic importance in the setting of antiangiogenesis therapy deserves to be studied in prospective trials.
Targeted Oncology – Springer Journals
Published: Apr 15, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.